Skip to main content
Top
Published in: Journal of Nuclear Cardiology 5/2020

01-10-2020 | Editorial

Dipyridamole infusion protocols for absolute myocardial blood flow quantitation by PET

Author: René R. Sevag Packard, MD, PhD

Published in: Journal of Nuclear Cardiology | Issue 5/2020

Login to get access

Excerpt

In this issue of the Journal of Nuclear Cardiology, F. Harel et al compare the effect of two dipyridamole dosing protocols on absolute myocardial blood flow (MBF).1 Patients were retrospectively identified over a 12-month period in a single center, and only those patients who had a coronary artery calcium (CAC) score available and whose CAC score was 0 were retained for analyses. Additional exclusion criteria including myocardial perfusion imaging (MPI) scans with a sum stress score > 3, and body mass index (BMI) > 45, were applied. In the first half of the study period, patients underwent a 4-minute dipyridamole infusion protocol (n = 65, standard dipyridamole dose of 0.56 mg/kg over 4 minutes), and during the second half, patients underwent a 5-minute protocol (n = 82, higher dipyridamole dose of 0.70 mg/kg over 5 minutes). 82Rb-chloride was used as the positron emission tomography (PET) radiopharmaceutical in all patients. …
Literature
2.
go back to reference Joseph J, Velasco A, Hage FG, Reyes E. Guidelines in review: Comparison of ESC and ACC/AHA guidelines for the diagnosis and management of patients with stable coronary artery disease. J Nucl Cardiol 2018;25:509-15.CrossRef Joseph J, Velasco A, Hage FG, Reyes E. Guidelines in review: Comparison of ESC and ACC/AHA guidelines for the diagnosis and management of patients with stable coronary artery disease. J Nucl Cardiol 2018;25:509-15.CrossRef
3.
go back to reference Gibbons RJ. Comparison of ESC and ACC/AHA guidelines for the diagnosis and management of patients with stable coronary heart disease: Are the differences clinically relevant? An American perspective. J Nucl Cardiol 2018;25:516-20.CrossRef Gibbons RJ. Comparison of ESC and ACC/AHA guidelines for the diagnosis and management of patients with stable coronary heart disease: Are the differences clinically relevant? An American perspective. J Nucl Cardiol 2018;25:516-20.CrossRef
4.
go back to reference American Society of Nuclear Cardiology. MedAxiom nuclear survey 2013. J Nucl Cardiol 2014;21(Suppl):5-88. American Society of Nuclear Cardiology. MedAxiom nuclear survey 2013. J Nucl Cardiol 2014;21(Suppl):5-88.
5.
go back to reference Dilsizian V, Gewirtz H, Paivanas N, Kitsiou AN, Hage FG, Crone NE, Schwartz RG. Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies. J Nucl Cardiol 2015;22:1198-213.CrossRef Dilsizian V, Gewirtz H, Paivanas N, Kitsiou AN, Hage FG, Crone NE, Schwartz RG. Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies. J Nucl Cardiol 2015;22:1198-213.CrossRef
6.
go back to reference Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol 2016;23:606-39.CrossRef Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol 2016;23:606-39.CrossRef
7.
go back to reference Zijlstra F, Juilliere Y, Serruys PW, Roelandt JR. Value and limitations of intracoronary adenosine for the assessment of coronary flow reserve. Catheter Cardiovasc Diagn 1988;15:76-80.CrossRef Zijlstra F, Juilliere Y, Serruys PW, Roelandt JR. Value and limitations of intracoronary adenosine for the assessment of coronary flow reserve. Catheter Cardiovasc Diagn 1988;15:76-80.CrossRef
8.
go back to reference Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD. Effects of adenosine on human coronary arterial circulation. Circulation 1990;82:1595-606.CrossRef Wilson RF, Wyche K, Christensen BV, Zimmer S, Laxson DD. Effects of adenosine on human coronary arterial circulation. Circulation 1990;82:1595-606.CrossRef
9.
go back to reference Kinsella D, Troup W, Mc GM. Studies with a new coronary vasodilator drug: persantin. Am Heart J 1962;63:146-51.CrossRef Kinsella D, Troup W, Mc GM. Studies with a new coronary vasodilator drug: persantin. Am Heart J 1962;63:146-51.CrossRef
10.
go back to reference West JW, Bellet S, Manzoli UC, Mueller OF. Effects of persantin (RA8), a new coronary vasodilator, on coronary blood flow and cardiac dynamics in the dog. Circ Res 1962;10:35-44.CrossRef West JW, Bellet S, Manzoli UC, Mueller OF. Effects of persantin (RA8), a new coronary vasodilator, on coronary blood flow and cardiac dynamics in the dog. Circ Res 1962;10:35-44.CrossRef
11.
go back to reference Tauchert M. Coronary reserve capacity and maximum oxygen consumption of the human heart. Basic Res Cardiol 1973;68:183-223.CrossRef Tauchert M. Coronary reserve capacity and maximum oxygen consumption of the human heart. Basic Res Cardiol 1973;68:183-223.CrossRef
12.
go back to reference Gould KL, Westcott RJ, Albro PC, Hamilton GW. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilatation. 2. Clinical methodology and feasibility. Am J Cardiol 1978;41:279-87.CrossRef Gould KL, Westcott RJ, Albro PC, Hamilton GW. Noninvasive assessment of coronary stenoses by myocardial imaging during pharmacologic coronary vasodilatation. 2. Clinical methodology and feasibility. Am J Cardiol 1978;41:279-87.CrossRef
13.
go back to reference Rossen JD, Quillen JE, Lopez AG, Stenberg RG, Talman CL, Winniford MD. Comparison of coronary vasodilation with intravenous dipyridamole and adenosine. J Am Coll Cardiol 1991;18:485-91.CrossRef Rossen JD, Quillen JE, Lopez AG, Stenberg RG, Talman CL, Winniford MD. Comparison of coronary vasodilation with intravenous dipyridamole and adenosine. J Am Coll Cardiol 1991;18:485-91.CrossRef
14.
go back to reference Wilson RF, Laughlin DE, Ackell PH, Chilian WM, Holida MD, Hartley CJ, et al. Transluminal, subselective measurement of coronary artery blood flow velocity and vasodilator reserve in man. Circulation 1985;72:82-92.CrossRef Wilson RF, Laughlin DE, Ackell PH, Chilian WM, Holida MD, Hartley CJ, et al. Transluminal, subselective measurement of coronary artery blood flow velocity and vasodilator reserve in man. Circulation 1985;72:82-92.CrossRef
15.
go back to reference Rossen JD, Simonetti I, Marcus ML, Winniford MD. Coronary dilation with standard dose dipyridamole and dipyridamole combined with handgrip. Circulation 1989;79:566-72.CrossRef Rossen JD, Simonetti I, Marcus ML, Winniford MD. Coronary dilation with standard dose dipyridamole and dipyridamole combined with handgrip. Circulation 1989;79:566-72.CrossRef
16.
go back to reference Chan SY, Brunken RC, Czernin J, Porenta G, Kuhle W, Krivokapich J, et al. Comparison of maximal myocardial blood-flow during adenosine infusion with that of intravenous dipyridamole in normal men. J Am Coll Cardiol 1992;20:979-85.CrossRef Chan SY, Brunken RC, Czernin J, Porenta G, Kuhle W, Krivokapich J, et al. Comparison of maximal myocardial blood-flow during adenosine infusion with that of intravenous dipyridamole in normal men. J Am Coll Cardiol 1992;20:979-85.CrossRef
17.
go back to reference Kubo S, Tadamura E, Toyoda H, Mamede M, Yamamuro M, Magata Y, et al. Effect of caffeine intake on myocardial hyperemic flow induced by adenosine triphosphate and dipyridamole. J Nucl Med 2004;45:730-8. Kubo S, Tadamura E, Toyoda H, Mamede M, Yamamuro M, Magata Y, et al. Effect of caffeine intake on myocardial hyperemic flow induced by adenosine triphosphate and dipyridamole. J Nucl Med 2004;45:730-8.
18.
go back to reference Johnson NP, Gould KL. Regadenoson versus dipyridamole hyperemia for cardiac PET imaging. JACC Cardiovasc imaging 2015;8:438-47.CrossRef Johnson NP, Gould KL. Regadenoson versus dipyridamole hyperemia for cardiac PET imaging. JACC Cardiovasc imaging 2015;8:438-47.CrossRef
19.
go back to reference Villines TC, Hulten EA, Shaw LJ, Goyal M, Dunning A, Achenbach S, et al. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography. Results from the CONFIRM (Coronary CT angiography evaluation for clinical outcomes an international multicenter) registry. J Am Coll Cardiol 2011;58:2533-40.CrossRef Villines TC, Hulten EA, Shaw LJ, Goyal M, Dunning A, Achenbach S, et al. Prevalence and severity of coronary artery disease and adverse events among symptomatic patients with coronary artery calcification scores of zero undergoing coronary computed tomography angiography. Results from the CONFIRM (Coronary CT angiography evaluation for clinical outcomes an international multicenter) registry. J Am Coll Cardiol 2011;58:2533-40.CrossRef
20.
go back to reference Goudarzi B, Fukushima K, Bravo P, Merrill J, Bengel FM. Comparison of the myocardial blood flow response to regadenoson and dipyridamole: A quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET. Eur J Nucl Med Mol Imaging 2011;38:1908-16.CrossRef Goudarzi B, Fukushima K, Bravo P, Merrill J, Bengel FM. Comparison of the myocardial blood flow response to regadenoson and dipyridamole: A quantitative analysis in patients referred for clinical 82Rb myocardial perfusion PET. Eur J Nucl Med Mol Imaging 2011;38:1908-16.CrossRef
21.
go back to reference Maddahi J, Packard RRS. Cardiac PET perfusion tracers: Current status and future directions. Semin Nucl Med 2014;44:333-43.CrossRef Maddahi J, Packard RRS. Cardiac PET perfusion tracers: Current status and future directions. Semin Nucl Med 2014;44:333-43.CrossRef
22.
go back to reference Dorbala S, Di Carli MF. Cardiac PET perfusion: Prognosis, risk stratification, and clinical management. Semin Nucl Med 2014;44:344-57.CrossRef Dorbala S, Di Carli MF. Cardiac PET perfusion: Prognosis, risk stratification, and clinical management. Semin Nucl Med 2014;44:344-57.CrossRef
23.
go back to reference Murthy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Neto S, Chareonthaitawee P, et al. Clinical quantification of myocardial blood flow using PET: Joint position paper of the SNMMI cardiovascular council and the ASNC. J Nucl Cardiol 2018;25:269-97.CrossRef Murthy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Neto S, Chareonthaitawee P, et al. Clinical quantification of myocardial blood flow using PET: Joint position paper of the SNMMI cardiovascular council and the ASNC. J Nucl Cardiol 2018;25:269-97.CrossRef
24.
go back to reference Murthy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Neto S, Chareonthaitawee P, et al. Clinical quantification of myocardial blood flow using PET: Joint position paper of the SNMMI cardiovascular council and the ASNC. J Nucl Med 2018;59:273-93.CrossRef Murthy VL, Bateman TM, Beanlands RS, Berman DS, Borges-Neto S, Chareonthaitawee P, et al. Clinical quantification of myocardial blood flow using PET: Joint position paper of the SNMMI cardiovascular council and the ASNC. J Nucl Med 2018;59:273-93.CrossRef
Metadata
Title
Dipyridamole infusion protocols for absolute myocardial blood flow quantitation by PET
Author
René R. Sevag Packard, MD, PhD
Publication date
01-10-2020
Publisher
Springer International Publishing
Published in
Journal of Nuclear Cardiology / Issue 5/2020
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-018-01554-2

Other articles of this Issue 5/2020

Journal of Nuclear Cardiology 5/2020 Go to the issue